

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Jovan-Embiricos Morana</u> (Last) (First) (Middle) <u>C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER</u> (Street) <u>GENEVA</u> <u>V8</u> <u>CH-1205</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TCR2 THERAPEUTICS INC. [TCRR]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>12/09/2019</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/09/2019		S		20,886	D	\$17.6511	371,299	I	By Fund ⁽¹⁾
Common Stock	12/09/2019		S		24,966	D	\$17.6511	443,835	I	By Fund ⁽²⁾
Common Stock	12/09/2019		S		19,070	D	\$17.6511	339,033	I	By Fund ⁽³⁾
Common Stock	12/09/2019		S		75,067	D	\$17.6511	1,334,504	I	By Fund ⁽⁴⁾
Common Stock	12/10/2019		S		8,479	D	\$17.6232	362,820	I	By Fund ⁽¹⁾
Common Stock	12/10/2019		S		10,135	D	\$17.6232	433,700	I	By Fund ⁽²⁾
Common Stock	12/10/2019		S		7,741	D	\$17.6232	331,292	I	By Fund ⁽³⁾
Common Stock	12/10/2019		S		30,475	D	\$17.6232	1,304,029	I	By Fund ⁽⁴⁾
Common Stock	12/11/2019		S		1,155	D	\$17.6525	361,665	I	By Fund ⁽¹⁾
Common Stock	12/11/2019		S		1,381	D	\$17.6525	432,319	I	By Fund ⁽²⁾
Common Stock	12/11/2019		S		1,054	D	\$17.6525	330,238	I	By Fund ⁽³⁾
Common Stock	12/11/2019		S		4,153	D	\$17.6525	1,299,876	I	By Fund ⁽⁴⁾
Common Stock								175,554	I	By Fund ⁽⁵⁾
Common Stock								90,026	I	By Fund ⁽⁶⁾
Common Stock								193,742	I	By Fund ⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	--	--------------------------------------	--	--------------------------------	--	--	---	--	--	---	--

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	V	5A. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5B. Date Exercisable and Expiration Date (Month/Day/Year)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
(Last)		(First)	(Middle)										
(Street)													
GENEVA		V8	CH-1205	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
(City)		(State)	(Zip)										
1. Name and Address of Reporting Person*													
Globeways Holdings Ltd													
(Last)		(First)	(Middle)										
3RD FLOOR, GENEVE PLACE, WATERFRONT DR PO BOX 3175, ROAD TOWN, TORTOLA, BVI													
(Street)													
GENEVA		V8	CH-1205										
(City)		(State)	(Zip)										
1. Name and Address of Reporting Person*													
Globeways Holdings II Ltd													
(Last)		(First)	(Middle)										
3RD FLOOR, GENEVE PLACE, WATERFRONT DR PO BOX 3175, ROAD TOWN, TORTOLA, BVI													
(Street)													
GENEVA		V8	CH-1205										
(City)		(State)	(Zip)										
1. Name and Address of Reporting Person*													
F2 Capital I 2015 Ltd													
(Last)		(First)	(Middle)										
C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER													
(Street)													
GENEVA		V8	CH-1205										
(City)		(State)	(Zip)										
1. Name and Address of Reporting Person*													
F2 Captial I 2017 Ltd													
(Last)		(First)	(Middle)										
C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER													
(Street)													
GENEVA		V8	CH-1205										
(City)		(State)	(Zip)										
1. Name and Address of Reporting Person*													
F2 MG Ltd													
(Last)		(First)	(Middle)										
C/O LJ FIDUCIARY, 8, RUE SAINT-LEGER													
(Street)													
GENEVA		V8	CH-1205										

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
F2 - TPO Investments LLC		
(Last)	(First)	(Middle)
C/O SINGER MCKEON, 8 WEST 38TH STREET, SUITE 1001		
(Street)		
NEW YORK	NY	10018
(City)	(State)	(Zip)

Explanation of Responses:

1. The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
2. The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
3. The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
4. The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
5. The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
6. The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
7. The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Remarks:

/s/ Morana Jovan-Embiricos	12/11/2019
/s/ Morana Jovan-Embiricos for Globeways Holdings Limited	12/11/2019
/s/ Morana Jovan-Embiricos for Globeways Holdings II Limited	12/11/2019
/s/ Morana Jovan-Embiricos for F2 Capital I 2015 Limited	12/11/2019
/s/ Morana Jovan-Embiricos for F2 Capital I 2017 Limited	12/11/2019
/s/ Morana Jovan-Embiricos for F2 MG Limited	12/11/2019
/s/ Morana Jovan-Embiricos for F2-TPO Investments, LLC	12/11/2019

** Signature of Reporting Person	Date
----------------------------------	------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.